| Mineralocorticoid receptor antagonists in diabetic kidney disease—Mechanistic and therapeutic effects J Barrera-Chimal, I Lima-Posada, GL Bakris, F Jaisser Nature Reviews Nephrology 18 (1), 56-70, 2022 | 131 | 2022 |
| Gender differences in the acute kidney injury to chronic kidney disease transition I Lima-Posada, C Portas-Cortés, R Pérez-Villalva, F Fontana, ... Scientific reports 7 (1), 12270, 2017 | 69 | 2017 |
| Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical … J Barrera-Chimal, P Kolkhof, I Lima-Posada, J Alexandre, P Rossignol, ... Expert Opinion on Investigational Drugs 30 (11), 1141-1157, 2021 | 31 | 2021 |
| Pirfenidone prevents acute kidney injury in the rat I Lima-Posada, F Fontana, R Pérez-Villalva, N Berman-Parks, ... BMC nephrology 20, 1-9, 2019 | 27 | 2019 |
| Understanding the opposite effects of sex hormones in mediating renal injury I Lima‐Posada, NA Bobadilla Nephrology 26 (3), 217-226, 2021 | 23 | 2021 |
| Neutrophil gelatinase-associated lipocalin from macrophages plays a critical role in renal fibrosis via the CCL5 (chemokine ligand 5)-Th2 cells-IL4 (Interleukin 4) pathway B Bonnard, J Ibarrola, I Lima-Posada, A Fernández-Celis, M Durand, ... Hypertension 79 (2), 352-364, 2022 | 17 | 2022 |
| Mineralocorticoid receptor antagonism prevents the synergistic effect of metabolic challenge and chronic kidney disease on renal fibrosis and inflammation in mice R Palacios-Ramirez, I Lima-Posada, B Bonnard, M Genty, ... Frontiers in Physiology 13, 859812, 2022 | 12 | 2022 |
| HSP72 is an early biomarker to detect cisplatin and acetaminophen nephrotoxicity R Pérez-Villalva, J Barrera-Chimal, JC Aguilar-Carrasco, I Lima-Posada, ... Biomarkers 22 (6), 548-556, 2017 | 12 | 2017 |
| Resilience to acute kidney injury in offspring of maternal protein restriction LE García-Ortuño, J Barrera-Chimal, R Pérez-Villalva, JA Ortega-Trejo, ... American Journal of Physiology-Renal Physiology 317 (6), F1637-F1648, 2019 | 9 | 2019 |
| Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction I Lima-Posada, Y Stephan, M Soulié, R Palacios-Ramirez, B Bonnard, ... International Journal of Molecular Sciences 24 (3), 2536, 2023 | 7 | 2023 |
